Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
618 INR | +18.84% | +20.38% | +22.52% |
14/05 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
13/05 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2022 | 12K 1M | Sales 2023 | 19.45K 1.62M | Capitalization | 25B 2,087B |
---|---|---|---|---|---|
Net income 2022 | 1.22B 102B | Net income 2023 | 1.94B 162B | EV / Sales 2022 * | - |
Net Debt 2022 | 2.58B 216B | Net Debt 2023 | 1.52B 127B | EV / Sales 2023 | 13,63,395 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
12.9
x | Employees | 2,042 |
Yield 2022 * |
-
| Yield 2023 |
0.73% | Free-Float | 52.08% |
1 day | +18.84% | ||
1 week | +20.38% | ||
Current month | +20.45% | ||
1 month | +37.45% | ||
3 months | +22.06% | ||
6 months | +57.75% | ||
Current year | +22.52% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 17/22/17 | |
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 17/22/17 |
Piyush Lakhani
DFI | Director of Finance/CFO | - | 17/22/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 17/22/17 |
Chairman | 49 | 07/21/07 | |
Director/Board Member | 77 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/24/14 | 618 | +18.84% | 7,438,200 |
13/24/13 | 520 | +3.50% | 476,891 |
10/24/10 | 502.4 | +2.01% | 158,266 |
09/24/09 | 492.6 | -2.42% | 93,188 |
08/24/08 | 504.8 | -1.68% | 121,834 |
Delayed Quote NSE India S.E., May 14, 2024 at 05:19 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+22.52% | 564M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- AARTIPHARM Stock